Cartesian Therapeutics is on a quick pace in a hot space. Founded in 2016, the company has already grown its pipeline of RNA-engineered cell therapies to nine candidates across auto-immune, oncology, and respiratory disease indications. Four of them—Descartes-08 for myasthenia gravis, Descartes-11 and Descartes-08 for myeloma, and Descartes-30 for ARDS—have advanced to phase I/II clinical […]

Dr. Michael McCullar, CEO, and Dr. Hong Tang, Chief Medical Officer at OnQuality Pharmaceuticals, a clinical stage pharma company pioneering the discovery and development of targeted cancer supportive care therapies that address cancer treatment-related toxicities at the molecular level, discuss the company’s lead pipeline candidate, OQL011, the first targeted treatment for the severe cancer med […]

Despite headlines indicating recent growth, R&D productivity in the biotech and pharma industries has been in steady decline. So, why is an industry that was built on bold, visionary leaps of faith through much of the 20th century – think insulin, antibiotics, the Salk polio vaccine, the rise of biotechnology and monoclonal antibodies – struggling […]